MetLife Plunges 5.04% Amid Investor Sentiment Shift

On April 4, 2025, MetLife's stock experienced a significant drop of 5.04% in pre-market trading, indicating a notable shift in investor sentiment towards the company.

Congress Wealth Management LLC DE reduced its stake in MetLife by 48.4% during the fourth quarter, reflecting a strategic adjustment in its investment portfolio. This move suggests a potential lack of confidence in the company's near-term prospects.

JPMorgan lowered its price target for MetLife from $88 to $86, while maintaining an Overweight rating. This adjustment indicates a cautious outlook on the company's future performance, despite the firm's overall positive stance.

Brian Meredith from UBS maintained a Buy rating on MetLife with a price target of $98.00, highlighting the firm's continued optimism about the company's long-term growth potential.

UBS initiated coverage of MetLife with a Buy rating and a price target of $98, up from $94. The firm expressed a cautiously positive view on the life insurance sector, suggesting that MetLife's fundamentals remain strong.

MetLife announced that it will hold its first quarter 2025 earnings conference call and audio webcast, providing investors with an opportunity to gain insights into the company's financial performance and strategic direction.